Drug Trial Radar · NCT07529808
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
164
Planned (sponsor's estimate)
Start
Jul 16, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- BigHat Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.
Conditions
- Gastric Cancer
- Gastric Adenocarcinoma
- Gastric (Stomach) Cancer
- Gastroesophageal Adenocarcinoma
- Gastroesophageal Cancer (GC)
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction (GEJ) Cancer
- Gastrointestinal Cancer Metastatic
- Gastrointestinal Adenocarcinoma
- Gastrointestinal Cancers
- Colorectal (Colon or Rectal) Cancer
- Pancreatic Cancer
- CDH17-positive Advanced Solid Tumors
- Advanced Gastric Cancer
Interventions
BHB810Drug
Every 2 weeks IV administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) per Common Terminology Criteria for Adverse Events v6.0 (CTCAE v6.0)Time frame: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
- Incidence of participants who have a dose modification of BHB810 due to toxicityTime frame: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
- Overall Response Rate (ORR)Time frame: Screening through End of Treatment, an average of 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Duarte
Duarte, California · Recruiting
University of California at Los Angeles
Santa Monica, California · Not yet recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.